NCT02166905: A trial that was reported late by Roswell Park Cancer Institute
This trial has reported, although it was 214 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02166905 |
|---|---|
| Title | A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 10, 2014 |
| Completion date | Aug. 20, 2020 |
| Required reporting date | Aug. 20, 2021, midnight |
| Actual reporting date | March 22, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 214 |